Skip to Content

MenHibrix Approval History

FDA Approved: Yes (First approved June 14, 2012)
Brand name: MenHibrix
Generic name: Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine
Company: GlaxoSmithKline
Treatment for: Haemophilus influenzae Prophylaxis, Meningococcal Meningitis Prophylaxis

MenHibrix (Hib-MenCY-TT) is a combination vaccine for the active immunization of infants and young children 6 weeks through 18 months of age for the prevention of invasive diseases caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzae type b (Hib).

Development History and FDA Approval Process for MenHibrix

DateArticle
Jun 15, 2012Approval GSK Receives FDA Approval for MenHibrix
Dec  1, 2011Regulatory Update: Glaxosmithkline Submits Additional Information for Candidate Meningococcal and Hib Combination Vaccine
Sep 26, 2011Regulatory Update: GlaxoSmithKline Receives Complete Response Letter from FDA for MenHibrix meningococcal and Hib combination vaccine

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide